Read More

Merus Announced Based On The Company’s Current Operating Plan, Existing Cash, Cash Equivalents And Marketable Securities, Expected To Fund Merus’ Operations Into Second Half 2025

Merus N.V. (Nasdaq: MRUS) today provided its 2023 outlook. - As of year-end 2022, more than 150 patients with NRG1 gene fusion positive ("NRG1+") cancer have been treated with zenocutuzumab ("Zeno") monotherapy - Petosemtamab clinical update planned for first half of 2023

MRUS